A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
← catalyst calendarSponsored by Nektar Therapeutics (industry) · NKTR — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
94actual
Sites
26
Countries
Canada, Poland, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-02 | actual | When the study began enrolling |
| Primary completion | 2025-11-26 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alopecia Areata
Interventions
- Drug: Rezpegaldesleukin — also filed as REZPEG, NKTR-358, LY3471851 (formerly)
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent change from baseline in Severity of Alopecia Tool (SALT) score at Week 36
measured Baseline and Week 36
Permalink · NKTR's whole pipeline · Catalyst calendar · Every registered study · What changed